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Abstract: Fungi and the mycobiome are a fundamental part of the human microbiome that contributes
to human health and development. Despite this, relatively little is known about the mycobiome
of the preterm infant gut. Here, we have characterised faecal fungal communities present in 11
premature infants born with differing degrees of prematurity and mapped how the mycobiome
develops during early infancy. Using an ITS1 sequencing-based approach, the preterm infant gut
mycobiome was found to be often dominated by a single species, typically a yeast. Candida was
the most abundant genus, with the pathobionts C. albicans and C. parapsilosis highly prevalent and
persistent in these infants. Gestational maturity at birth affected the distribution and abundance
of these Candida, with hospital-associated C. parapsilosis more prevalent and abundant in infants
born at less than 31 weeks. Fungal diversity was lowest at 6 months, but increased with age and
change of diet, with food-associated Saccharomyces cerevisiae most abundant in infants post weaning.
This study provides a first insight into the fungal communities present within the preterm infant gut,
identifying distinctive features including the prominence of pathobiont species, and the influence age
and environmental factors play in shaping the development of the mycobiome.
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1. Introduction
The human gastrointestinal (GI) tract harbours a complex microbial ecosystem comprising a
vast number and array of bacteria, archaea, fungi, protozoa and viruses that constitute the intestinal
microbiota [1,2]. Most of what we currently know regarding the contribution the enteric microbiota
makes to human health and disease comes from the analysis of the prokaryome. Various studies of
bacterial constituents of the microbiota have provided evidence for their ability to influence various
physiological processes including digestion, micronutrient biosynthesis, energy homeostasis, pathogen
colonisation resistance, and maintenance of epithelial barrier integrity [3], and the development and
functional maturation of the host immune system [4]. Disruption of the prokaryome (dysbiosis) in
early life can have a profound and long-lasting impact on health later in life, including the development
of non-communicable illnesses, such as atopy and allergic disease (e.g., asthma), and metabolic
disorders [5–8].
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By comparison, far less is known about the mycobiome and fungal residents of the GI tract, and
their involvement in human health and disease. This is in part related to their low abundance [9]. In a
recent metagenomic study, fungi were estimated to make up approximately 0.1% of the microbiota in
the healthy adult GI tract [1]. In considering that fungi are larger in volume than bacteria, they are likely
to constitute a sizeable proportion of the intestinal microbiota biomass [10]. Thus, despite their low
abundance, fungi can have significant impacts on human health [11]. The yeast Saccharomyces boulardii,
a probiotic strain of S. cerevisiae, is frequently prescribed as an effective treatment for antibiotic-associated
diarrhoea and irritable bowel syndrome (IBS) [12–15]. In contrast, fungal dysbiosis and reduced
fungal diversity, coupled with increased levels of Candida parapsilosis and Pichia jadinii (C. utilis) has
been observed in paediatric cases of inflammatory bowel disease (IBD) [16]. IBD pathogenesis has
also been correlated with an increased Basidiomycota/Ascomycota ratio and increased abundance
of C. albicans [17]. Fungal dysbiosis has also been reported in colorectal adenoma, and in metabolic
syndrome and obesity [17–19]. Fungal pathobiont overgrowth leading to infection, often as a result
of prolonged antibiotic exposure, also poses a significant health risk, especially in immune deficient
individuals, such as those undergoing chemotherapy and solid organ transplantation [11].
Preterm infants represent a highly vulnerable and ‘at risk’ patient group, having endured disrupted
fetal development, with the final weeks/months of development occurring ex utero in a neonatal
intensive care unit (NICU). A shortened gestational period, shortened labour and possible delivery by
caesarean section are all factors that can contribute to reduced exposure to maternal vaginal and enteric
microbiotas [20,21]. Indeed, the bacterial composition of the preterm gut is distinct, characterised
by a reduced diversity and dominance of facultative anaerobes (e.g., Enterococcus and Staphylococcus
spp.) [22,23]. Preterm infants also have an underdeveloped immune system and an intestinal epithelial
barrier with increased permeability. Consequently, this makes them highly susceptible to nosocomial
infection, especially from the ‘ESKAPE’ pathogens, a group of virulent and multi-drug resistant bacteria
which include Enterococcus faecium, Klebsiella pneumoniae and Staphylococcus aureus [24]. In addition,
these infants are at increased risk of developing late-onset sepsis and necrotising enterocolitis [25–27].
Broad-spectrum antibiotics are also frequently administered to preterm infants in their first weeks of life.
However, an adverse effect of such treatment is increased susceptibility to fungal infections resulting
in significant morbidity and mortality [28]. These can arise either from overgrowth of resident fungal
pathobionts (e.g., C. albicans) or from horizontally acquired species within the hospital environment
(e.g., C. parapsilosis) [29–34]. To reduce the risk of such infections, prophylactic antifungals are routinely
administered in the first weeks of life to the highest risk preterm babies, specifically those born at
less than 27 weeks’ gestation and/or weighing less than 750 g, while they have an indwelling central
venous catheter.
In the present study, we developed laboratory protocols and a fungal analysis bioinformatics
pipeline to characterise the faecal mycobiome of a small cohort of young infants all born with differing
degrees of prematurity, over the course of a 12-month period in early infancy. The goal was to gain
a first insight into the composition and diversity of the preterm infant gut mycobiome, and how it
changes between the first 6 to 18 months’ postnatal life; an important developmental window in early
infant life.
2. Materials and Methods
2.1. Study Participants and Samples
The infant cohort comprised 11 infants, 5 females and 6 males, aged less than 2-years old. All were
born preterm at the Norfolk and Norwich University Hospital (NNUH), with gestational ages ranging
from 25 weeks (extremely preterm) to 36 weeks (late preterm), with a median age of 30 + 4 weeks.
All 11 infants were participants in the BAMBI study (Reference no: ‘2012/2013—42HT’), a longitudinal
microbiota profiling study to determine the impact of Bifidobacterium and Lactobacillus supplementation
on the bacterial composition of the preterm infant gut [35]. All subjects gave their informed consent
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for inclusion before they participated in the study. The study was conducted in accordance with
the Declaration of Helsinki, and the protocol was approved by the Quadram Institute Bioscience
Ethics Committee and in accordance with protocols by the National Research Ethics Service (NRES)
approved UEA/QIB Biorepository (License no: 11208). Clinical metadata for the infants including
gender, gestational age at birth, birthweight, mode of delivery, and postnatal antimicrobial treatment,
along with whether they received breastmilk and/or formula during their stay at the NNUH are
provided in Table S1.
2.2. DNA Extraction
Infant faecal samples were collected at three time points; 6 months, 12 months and 18 months and
were aliquoted and stored at −70 ◦C prior to processing and DNA extraction. Total microbial DNA
was extracted from ~200 mg of faeces using the FastDNA Spin Kit for Soil (MP Biomedicals, Irvine,
CA, USA) and following the manufacturer’s protocol. In addition, all samples were homogenized
using a FastPrep-24 benchtop instrument (MP Biomedicals) at 6.0 m/s for 3 × 1 min with 5 min resting
intervals on ice. Extracted DNA was quantified and quality checked using the Qubit 3.0 fluorometer
and associated Qubit dsDNA BR Assay Kit (Thermo Fisher, Waltham, MA, USA), as well as DNA
visualisation by stained agarose gel electrophoresis (1% agarose gel stained with Midori Green Direct
DNA Stain). A flowchart outlining the DNA extraction protocol is shown in Figure S1 (left hand panel).
2.3. ITS1 Amplification, Library Preparation and Sequencing
The fungal ITS1 region was amplified from 100 ng of faecal DNA by PCR using the ITS1F and
ITS2 primer set [36,37], with each primer modified at the 5′ end to include an Illumina adapter tail
using the following amplification conditions: 94 ◦C for 5 min; 35 cycles of 92 ◦C for 30 s, 55 ◦C for
30 s, and 72 ◦C for 45 s; and a final extension of 72 ◦C for 5 min. Amplification reactions were set
up in duplicate for each faecal DNA sample, and positive and negative controls were also included
in each PCR run (see Section 2.5). Following ITS1 PCR, a 0.7× SPRI purification using KAPA Pure
Beads (Roche, Wilmington, MA, USA) was performed and the purified DNA was eluted in 20 µL of
EB buffer (10 mM Tris-HCl). In a second PCR, library index primers were added using a Nextera
XT Index Kit v2 (Illumina, Cambridge, UK) and following the following amplification conditions:
95 ◦C for 5 min: 10 cycles of 95 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for 30 s; and a final extension of
72 ◦C for 5 min. Following PCR, libraries were quantified using the Invitrogen™ Quant-iT dsDNA
high sensitivity assay kit (Thermo Fisher) and run on a FLUOstar Optima plate reader (BMG Labtech,
Aylesbury, UK). Libraries were pooled following quantification in equal quantities. The final pool was
SPRI cleaned using 0.7× KAPA Pure Beads, quantified on a Qubit 3.0 fluorometer and run on a High
Sensitivity D1000 ScreenTape (Agilent Inc., Santa Clara, CA, USA) using the Agilent Tapestation 4200 to
calculate the final library pool molarity. The pool was then run, at a final concentration of 8 pM, on an
Illumina MiSeq instrument using the MiSeq® Nano v2 (2 × 250 bp) Kit (Illumina). All sequencing was
performed at the Quadram Institute Bioscience, Norwich. The raw data were analysed locally on the
MiSeq instrument using MiSeq reporter.
2.4. Mycobiome Characterisation
Illumina MiSeq reads were analysed using a hybrid pipeline using USEARCH [38] and QIIME 2 [39].
After removal of locus-specific primers and reads with ambiguous bases using fastp 0.20.0 [40],
the remaining reads were pooled, quality filtered and dereplicated using USEARCH. Identification of
representative sequences was performed using the UNOISE3 algorithm [41], to produce a set of amplicon
sequence variants (ASVs). A feature table was produced with USEARCH. Representative sequences and
the feature table were imported as QIIME 2 artifacts. QIIME 2 was used to assign the taxonomy using the
UNITE Fungal ITS database (release 04.02.2020) [42], to align ASVs using mafft [43] via “q2-alignment”,
and to construct a phylogeny with fasttree2 [44], using “q2-phylogeny”. Community composition was
assessed using R 3.6.2 [45] and the R package phyloseq [46]. The feature table, taxonomic classification,
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phylogeny and metadata were imported into R to create a phyloseq object. Every ASV with a zero
count in all samples was removed to assess alpha diversity measures. Community composition and
beta-diversity measures were assessed after removing samples with <7500 counts, transforming counts
to relative abundances and removing taxa with <5% relative abundances in all samples. A flowchart
outlining the main steps in the mycobiome analysis pipeline is shown in Figure S1 (right hand panel)
The raw Illumina ITS1 sequence data produced by the present study have been deposited at the
NCBI Short Reads Archive (SRA), under BioProject accession number PRJNA627184. All scripts used
in this study are available at https://github.com/quadram-institute-bioscience/bambi-its/.
2.5. Inclusion of Controls
Controls were included at each stage of this study. During DNA extraction, an empty bead-beating
tube was included and treated exactly the same as for the tubes containing faecal samples, and was
quantified and visualised similarly. This extraction control was included in the initial amplicon PCR
to assess that no ITS1 amplicon was produced. Negative (PCR dH2O) and positive controls (0.01 ng
C. albicans DNA) were included for all PCR reactions. Libraries were also prepared from the DNA
extraction control and from C. albicans DNA and were used as pipeline controls in the downstream
bioinformatic analyses.
3. Results
3.1. ITS1 Based Mycobiome Profiling and the Infant Gut Mycobiome
We developed a culture-independent protocol and bioinformatics pipeline to amplify and sequence
the fungal internal transcribed sequence (ITS) 1 region located between the 18 S and 5.8 S rRNA genes
to gain a better insight into the composition and diversity of the infant gut mycobiome in early life,
and how it changes over time. The protocol and pipeline was used to characterise the faecal fungal
communities present in 11 healthy young infants comprising five females (F1 to F5) and six males (M1
to M6), all of whom were born premature (see Table S1). Faecal samples were collected over a 12-month
period, at 6, 12 and 18 months. Following collection, samples were aliquoted and stored at −70 ◦C
until required. Although culture-dependent protocols were also employed in this study, prolonged
sample freezing was found to prevent the isolation of viable fungi. A total of 29 faecal samples were
obtained (for four infants only two samples were available) for ITS1 sequencing. A total of 1,609,183
quality-trimmed ITS1 reads were obtained, ranging from 8924 for infant F3, 18-month sample (F3_18) to
130,247 for M2_12, with a sample average of 55,489 reads (see Datasheet S1). One hundred and twelve
fungal taxa were detected, with the majority (86%) classified to the genus level or below. Two taxa
could not be assigned at the phylum level or below, and were classified as ‘Unidentified’ (see Datasheet
S1). The number of fungal taxa detected in each infant sample ranged from five to 37, with a sample
average of 15.8 (Table S2). A significant proportion of the fungi detected were infant and sample time
point-specific (47/112; 42.0%).
At the phylum level, >98% of fungi belonged to either Ascomycota or Basidiomycota. Sixty taxa
were ascomycetes, 44 of which could be identified to species level, while 50 taxa were basidiomycetes,
and 34 were identified to species level (Table S3). Ascomycota was the predominant phylum, accounting
for 60% of all ITS1 reads, and was dominant in many of the samples (Figure 1a). Ascomycetes were the
most abundant fungi at all collection timepoints (Figure S2).
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Figure 1. Bar charts of the relatively most abundant fungal taxa in the preterm infant gut at (a) phylum
level and (b) genus level.
Candida was present in all 29 infant samples (Table S4). In some samples, such as the
6-month samples from infants F1, M1, M3 and M5, Candida was the predominant genus (Figure 1b).
Other prevalent genera, of varying abundance, included Davidiella (23), Penicillium (21), Aspergillus
(18), Saccharomyces (15) and Debaryomyces (14) (Table S4), some of which dominated individual
samples (e.g., Debaryomyces, F1_12; Saccharomyces, F3_18) (Figure 1b). Amongst the Basidiomycota,
Baeospora (e.g., B. myosura) was the most abundant and prevalent genus, present in all but two samples
(Figure 1b; Table S4). Five other prevalent basidiomycetous genera were Malassezia (13), Rhodotorula
(12), Filobasidium (9), Naganishia (8) and Vishniacozyma (8). However, all of these genera were present
in low abundance, with individual mean abundances of 0.2 to 2.9% (Filobasidium and Naganishia,
respectively) with many basidiomycetous genera occurring at abundances of <0.2% (Table S4).
Among the ten most abundant genera of either phylum, six were yeast genera (i.e., Candida,
Debaryomyces, Meyerozyma, Naganishia, Rhodotorula and Saccharomyces) (Figure 1b). Of the 78 fungi
resolved to species level, six of the most abundant were yeasts. Moreover, these yeasts were
subdivided into two distinct groups, human-associated (e.g., Candida albicans) and food-related
(e.g., Saccharomyces cerevisiae) (Table S5).
3.2. Prevalence of Opportunistic Candida Pathogens
Candida accounted for 28.8% of all fungal reads, and was present in every infant sample, ranging
from 0.02 to 97.1% abundance (in F4_12 and M1_06, respectively). In total, six Candida species were
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identified, including most notably C. albicans, C. metapsilosis, C. parapsilosis and C. tropicalis, all of
which are human-associated and fungal pathobionts [47]. In the case of the other two species, namely
C. natalensis and C. railenensis, both were discounted from further analyses based on their inability to
survive above 30 ◦C [35].
Of the four human-associated Candida, at least one species was present in every infant sample
with 79% of the samples containing two or more species with C. albicans and C. parapsilosis found in
17/23 (74%) samples (Figure 2). Overall, C. parapsilosis was the most abundant (mean of 13.3%) and
prevalent (90%). Only three infants did not carry C. parapsilosis at all timepoints (Figure 2). C. albicans
was the second most abundant (mean of 10.9%) and prevalent species (66%). In contrast, C. metapsilosis
and C. tropicalis were less common, present in four and eight samples, respectively. Despite its low
prevalence, C. metapsilosis was nevertheless the most abundant species (70.1%) in the 6-month sample
of infant M5 (Figure 2). This infant was unique as he was the only member of the cohort categorized as
‘high risk’, based on his gestational age at birth (<27 weeks) and a birthweight of <750 g. Such ‘high
risk’ infants routinely receive prophylactic antifungals while fitted with an indwelling central venous
catheter to help reduce the risk of fungal infection, and fluconazole was the prophylactic antifungal
administered to this infant (from day 7 to 36; see Table S1).
Figure 2. Bubble plot depicting the prevalence and relative abundance of opportunistic pathogenic
Candida species in the preterm infant gut mycobiome (Calb, C. albicans; Cmeta, C. metapsilosis; Cpara,
C. parapsilosis; Ctrop, C. tropicalis).
All infants were born premature and their gestational ages (GA) at birth ranged from 25 to 36
weeks (Table S1). When the longitudinal samples were re-ordered from earliest to latest GA, there were
clear differences between the distribution and abundance of the four Candida species; most notably
between C. albicans and C. parapsilosis (Figure 3). For the six infants born at <31 weeks, C. parapsilosis
was the more prevalent, present in 14/16 samples (~87%), compared to 9 samples (~56%) for C. albicans.
Furthermore, C. parapsilosis was also more abundant than C. albicans in these infants (12.6% versus 2.7%,
respectively). In contrast, for the five infants born at 31 weeks or later, while both species were present
in a comparable number of samples (C. albicans, 10; C. parapsilosis, 12), C. albicans was more abundant
(C. albicans, 21.0%; C. parapsilosis, 14.1%). Whereas the mean relative abundance of C. parapsilosis
remained at a similar level between the two infant groups (GA: <31 weeks, 12.6%; ≥31 weeks, 14.1%),
it increased ~8-fold for C. albicans (GA: <31 weeks, 2.7%; ≥31 weeks, 21.0%).
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Figure 3. Bar graph of the prevalence and abundance of human-associated Candida species in the
preterm infant gut mycobiome. Samples ordered according to infant gestational age at birth.
3.3. Fungal Species Persistence
Fungal persistence in serial samples is indicative of successful colonisation. To investigate
this further, longitudinal samples from each individual infant were examined focusing on taxa
identified to species level. A total of 23 species were identified of which nine appeared infant-specific
(e.g., Aspergillus ruber, infant M1), with 14 re-occurring in two or more infants (e.g., Debaryomyces hansenii;
infants F1, F3, M1, M3 and M6) (see Table S6).
By applying the criteria of survivability and growth at body temperature, 14 fungi were discounted
as transients based on their inability to grow at 37 ◦C. The remaining nine species were further
subdivided into three groups according to whether they were foodborne, of environmental origin or
human-associated of which the latter group contained the majority of species. In addition to C. albicans,
C. parapsilosis and C. tropicalis, which are considered human-associated species [47,48], this group also
included Malassezia restricta, Meyerozyma guiliiermondi and Wickerhamomyces onychis (Table 1). The most
persistent and re-occurring species able to grow at 37 ◦C were C. albicans (7 infants), C. parapsilosis (11),
D. hansenii (5), M. restricta (4) and S. cerevisiae (5).
Table 1. Persistent fungi. Species detected at two or more collection timepoints (i.e., at 6-, 12- and/or
18-months), with the ability to grow at body temperature.
Species Category Infant #
Aspergillus ruber Environmental 1
Candida albicans Human-associated 7
Candida parapsilosis Human-associated 11
Candida tropicalis Human-associated 2
Debaryomyces hansenii1 Foodborne 5
Malassezzia restricta Human-associated 4
Meyerozyma guilliermondii Human-associated 2
Saccharomyces cerevisiae1 Foodborne/Probiotic 2 5
Wickerhamomyces onychis1 Human-associated 1
# Number of infants carrying the species; 1 Growth at 37 ◦C is strain variable; 2 Saccharomyces boulardii, a probiotic
strain of S. cerevisiae.
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3.4. Fungal Community Dynamics
To determine how fungal diversity changed over time, the longitudinal samples were subdivided
according to time of collection. The analysis showed that as the infants aged and their diet changed
species diversity (as taxa/sample) increased, albeit gradually (see Table S2). This was irrespective of
whether all 29 samples were included, or if the analysis was restricted to the infants for which three
longitudinal samples were available. The increase in diversity was most marked in the seven infants
from whom three samples were obtained, with the mean number of taxa per sample increasing from
14.4 at 6 months, to 20.6 at 18 months with the largest range in diversity being at 12 months (range:
5 to 37 taxa/sample) (Figure 4). Due to the small infant cohort size, limited number of samples, and
difference in sequencing depth between samples, the observed increase in fungal diversity did not
reach significance. However, when the analyses were repeated using only samples with >10,000 reads
and the data rarefied, then the alpha diversity (using Shannon metrics) still increased as the infants
aged (see Figure S3).
Figure 4. Fungal alpha-diversity depicted by a box-and-whisker plot showing number of taxa detected
in each faecal sample for infants with 3 longitudinal samples. The horizontal line represents the median
marker and ‘×’ represents the mean marker.
Two notable fungi which increased in prevalence over the 12-month study period were D. hansenii
and S. cerevisiae. While both species were present at all three timepoints, the majority of infant samples
in which they were detected, either individually or together, were at the 12 and 18-month timepoints
(D. hansenii, 11/14; S. cerevisiae, 12/15) (Figure 5 and Table S7). The lowest abundance, of either species,
was at 6 months whereas the highest abundance of either species was at 12 months. Indeed, S. cerevisiae
was the dominant species in three of the 12-month samples, while D. hansenii accounted for almost all
(99.4%) ITS1 reads in F1_12 (Figure 5).
Figure 5. Bar chart depicting the prevalence and abundance of D. hansenii and S. cerevisiae in the
preterm infant gut at between 6- and 18-months of age.
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4. Discussion
Preterm infants, with their immature immune system and an intestinal epithelial barrier of
increased permeability, represent a highly vulnerable paediatric patient group. A shortened gestational
period, disrupted in utero development, possible delivery by Caesarean section and significant
antibiotic treatments all contribute to the bacterial composition of the preterm gut being distinct,
typically characterised by reduced diversity and dominated by facultative anaerobes [22,23]. However,
compared to the well-characterised bacterial community, very little is known about the mycobiome of
the premature infant gut. Furthermore, while bacterial composition has been shown to differ during the
first few weeks of life based on gestational maturity at birth [49], little is known about how gestational
age affects and possibly shapes the enteric mycobiota of these infants.
To begin addressing this shortfall, we developed a workflow and protocols to characterise
the fungal communities present in a cohort of infants, born with differing degrees of prematurity,
and mapped how they develop during the first 18 months of life. Our findings reveal that the fungal
communities within the preterm infant GI tract exhibit considerable diversity, were infant-specific,
and characterised by the dominance of a single taxon and the presence of pathobiont Candida species.
The makeup of the mycobiome is also influenced by GA and early life environmental factors.
Over 100 different fungi were identified with the majority classified to either the genus or species
level. Despite this considerable diversity, many of the infant faecal samples contained a relatively
low number of taxa, and were often dominated by a single taxon, typically a yeast from the genera
Candida, Debaryomyces or Saccharomyces. (e.g., C. albicans, C. parapsilosis, D. hansenii or S. cerevisiae),
with Candida colonisation influenced by the gestational age of the neonate at birth. Many of the fungi
were infant-specific, often present in very low abundance, found at only one timepoint over the course
of the 12-month study period and were not detected in the DNA extraction control. For those taxa
for which a species identity could be determined (~70%), many were environmental fungi based on
the fact they are commonly found in soil, the air, and associated with plants either as pathogens or
saprophytes. Many of these fungi are incapable of growth at 37 ◦C making their presence in the infant
samples incidental, due to either ingestion (as foodborne contaminants) or through spore inhalation and
subsequent ingestion. This is perhaps best exemplified by the spore-forming species Davidiella tassiana
(anamorph—Cladosporium herbarum) and Baeospora myosura repeatedly detected in our preterm infant
cohort, although often at low abundance. Their inability to grow at human body temperature means
that their presence is most likely incidental due to spore ingestion (e.g., as foodborne contaminants).
At a phylum level, the preterm infant gut mycobiome comprises exclusively of fungi from the
Ascomycota and Basidiomycota phyla, with Ascomycota dominating at all three timepoints over
the 12 months. This dominance was largely due to the presence of the genera Candida, Davidiella,
Debaryomyces, Penicillium and Saccharomyces, which collectively accounted for over 50% of all fungal
reads. The dominance of Ascomycota and Basidiomycota in the healthy human GI tract, of both infants
and adults, has been reported previously in several studies, with these fungi also being dominant
members of the skin, vaginal and oral cavity mycobiomes [10,33,50–53]. Collectively, this suggests
members of these phyla are well-suited for persisting within and on the human host. In addition,
the mammalian GI tract appears to be the primary ecological niche for a number of human-associated
Candida including most notably C. albicans, a species rarely found in the environment [48,54].
Candida accounted for over a quarter of all the fungal reads and it was the most prevalent genus,
being detected in every infant sample. This is in line with Candida species and C. albicans in particular
being frequently identified both in the infant and adult gut [33,34,53,55,56], as well as in other body
sites, including the oral cavity and vagina [50,51,57]. Six Candida species were identified in the preterm
infant cohort, including C. albicans, C. metapsilosis, C. parapsilosis and C. tropicalis, all of which are
human-associated and fungal pathobionts [47]. Indeed, at least one of these four Candida species
was detected in every infant sample with the majority containing at least two of the species, most
commonly C. albicans and C. parapsilosis. This is consistent with preterm infants having higher Candida
colonisation rates compared to their full-term counterparts [32]. Although infrequently detected,
J. Fungi 2020, 6, 273 10 of 16
C. metapsilosis was most notable for being the dominant Candida pathobiont in the most premature
infant (25 weeks), which uniquely received the prophylactic antifungal fluconazole in the first month
of life. Our study also revealed that Candida colonisation persists well beyond the first few weeks after
birth, when many preterm infants, especially those born <28 weeks, remain hospitalised and highly
susceptible to nosocomial bacterial or fungal infection. Indeed, in two of the preterm infants, Candida
are the dominant fungi at 18 months after birth (Infant M2, C. parapsilosis; M4, C. albicans).
Although C. albicans is a common commensal of both the human GI tract and oral cavity [58] and
is a predominant member of the vaginal mycobiome [59], C. parapsilosis was the most prevalent Candida
species in the preterm infant cohort. Of the 11 preterm infants studied, eight carried C. parapsilosis
at all timepoints over the 12 months. It was also more abundant in those infants born at <31 weeks
(i.e., very/extremely preterm), whereas C. albicans abundance was generally higher in infants born at
≥31 weeks (i.e., moderately preterm to near term).
To date, little data is available relating to the composition of the enteric mycobiome of infants
born full term. However, in a recent longitudinal study, where the anal, oral and skin mycobiomes
of a cohort of term infants were characterized over the first month of life, C. parapsilosis along with
C. albicans were both found to be prevalent in the anal mycobiome of these infants, present in 95% and
85% of samples, respectively [33]. This previous study also found C. tropicalis to be highly prevalent
in these infants (present in >90% anal samples), which is in marked contrast to the results from our
study, where this species was detected in just over a quarter of infant samples. A possible explanation
for this marked difference could be the fact the authors found C. tropicalis, as well as C. albicans, to
be present in every maternal vaginal mycobiome [33], and thus its prevalence in these infants could
reflect the fact they were all born to term. This may also account for why C. albicans, again present in
every pregnant mother, was more prevalent in the term-born infants compared to the preterm infants
in our study (85% and 66%, respectively) [33].
Whilst C. parapsilosis is often detected in the human gut [10,33,60], it is primarily a skin
commensal [61] and is often present in the hospital environment, and in particular in the neonatal
intensive care unit (NICU). C. parapsilosis is, therefore, considered a significant human pathogen,
particularly of preterm neonates. Multiple risk factors including prolonged hospitalisation, very low
birth weight (<1500 g), parenteral nutrition and the use of indwelling intravenous catheters, hand
carriage and indirect (horizontal) transmission contribute to the vulnerability of preterm infants to
C. parapsilosis infection [29,62,63]. All but one of our preterm cohort were born with either very-
or extremely low birth weight, and required lengthy hospitalisation after birth (mean hospital stay:
49 days). The prevalence of C. parapsilosis in these infants may therefore result from hospital acquisition
rather than vertical transfer from mother to offspring, either before or during delivery. Considering that
all preterm infants endure disrupted fetal development, with the final weeks/months of development
occurring ex utero and with little exposure to the maternal mycobiota, this may account for why
C. albicans, a key member of the vaginal mycobiome [59], was less abundant than C. parapsilosis in these
infants. However, in the absence of accompanying maternal mycobiota data, we cannot discount the
possibility that these findings were due to or influenced by the composition of the maternal mycobiome.
Based on the growth requirements of individual fungi, we were able to discriminate between
transient versus persistent colonisers of the preterm infant gut. On this basis, only nine species
possessed the ability to grow at 37 ◦C, representing potential stable colonisers of which C. albicans and
C. parapsilosis occurred the most, and are often found in the adult human gut [33,34,53,55,56].
Three other notable persistent yeast species in the preterm infants were D. hansenii, M. restricta
and S. cerevisiae. D. hansenii is a ubiquitous osmotolerant fungus, highly prevalent in dairy products
and often used in the food industry as a cheese yeast [64,65]. D. hansenii has also been isolated from the
skin and breast milk, and is a dominant member of the infant gut mycobiota during the breast-feeding
period [10,65–67]. It has also been cultured from human faeces and some strains are reported to grow
at 37 ◦C [64]. Collectively, this would suggest D. hansenii or at least certain strains of the species have
the capacity to survive and colonise the preterm infant GI tract.
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M. restricta is a lipophilic basidiomycete and, like other members of the genus, is considered to be
one of the principle fungal constituents of the skin microbiota of infants and adults [52,68,69]. Thus,
as a prevalent skin commensal, M. restricta acquisition can occur by either vertical transmission (mother
to offspring) or horizontal transfer (healthcare worker to offspring). M. restricta has also been detected
in human breast milk as well as the GI tract [10,53,60,66,67,70]. Whilst its presence in breast milk may
be due to possible transfer from surrounding maternal skin, the fact it has been detected repeatedly in
the human gut would indicate it can also colonise the GI tract [10,53,60,70]. This is supported by our
finding that M. restricta is prevalent and persistent in four of the preterm infants.
S. cerevisiae persisted in almost half of the infant cohort, and increased in abundance over time in
two of the infants, indicative of successful colonisation. The findings that S. cerevisiae is frequently
detected in the adult human GI tract [10,48,71] and that some strains grow well at 37 ◦C [66,72] is
consistent with S. cerevisiae being a stable coloniser of the human GI tract. Countering this claim for
S. cerevisiae being a human GI tract commensal is the recent finding that S. cerevisiae could not be
detected in stool samples of four healthy Western adults fed a S. cerevisiae-free diet [73]. This finding
and study suggests it is a transient coloniser of the human GI tract, with its presence being dependent
upon sustained consumption of food containing S. cerevisiae (e.g., bread) [48]. Further studies are
required to establish the true nature of the relationship between S. cerevisiae and the human mycobiome.
Overall, the diversity of the preterm infant gut mycobiome is low, with community composition
differing between infants. Similar findings have been reported for full term infants [10,33] suggesting
that in early life the infant gut is populated by a relatively small number of fungal species, irrespective
of whether the infant is born premature or to term. Through longitudinal sampling, we observed
that as the infants aged, so the diversity and species richness of their respective gut mycobiomes
also increased, albeit gradually as noted in full term infants [10]. Diet is likely to be a major factor
and driver of this increased diversity. Between 6 and 9 months of age, most babies typically begin
weaning (or complimentary feeding), a time when they are first introduced to solid foods. At this
point in development, and over the coming months, not only does their diet increase in complexity,
from purely milk-based, but these infants are also exposed to a variety of different foodborne microbes
including fungi. The persistence of D. hansenii and S. cerevisiae that are both closely associated with
food in our cohort highlight the importance of the post-weaning infant diet and the role it can play in
fungal acquisition and in shaping the early life preterm infant gut mycobiome.
5. Conclusions
This study describes the development of a protocol and pipeline workflow for the characterisation
of the human faecal mycobiome and its application to provide the first detailed insight into the fungal
communities present within the preterm infant gut in early life. Our findings show how colonisation of
the preterm infant gut is influenced by gestational age, and how age and diet impact on the subsequent
development and diversity of the gut mycobiome. A characteristic feature of the preterm infant gut
mycobiome is the prominence of the pathobiont C. parapsilosis, a prevalent hospital-associated fungal
pathobiont. This study paves the way for further investigations of the developing enteric mycobiome
and the importance and impact of gestational maturity at birth on community composition, as well as
early antibiotic/antifungal prophylaxis in establishing both a healthy mycobiome and microbiome.
Furthermore, while probiotic supplementation in preterm infants has been shown to have a positive
impact, leading to a Bifidobacterium-dominated gut with a lower abundance of bacterial pathobionts,
no such study has yet been carried out to investigate the effect of such treatment on the gut mycobiota
of these infants.
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